<i>KRAS</i>: Druggable at Last
Benjamin Herzberg, Gulam A. Manji
Abstract
The approval of adagrasib for non–small cell lung cancer is a milestone in drug development. This commentary highlights the history of the research that led to this breakthrough that will help many patients with KRAS-mutated cancers to live longer and better.
Topics & Concepts
MedicineKRASMilestoneDruggabilityDrug developmentLung cancerCancerOncologyDrugInternal medicinePharmacologyColorectal cancerGeneticsArchaeologyGeneHistoryBiologyLung Cancer Treatments and MutationsCancer therapeutics and mechanismsLung Cancer Research Studies